Cheplapharm Drug Patent Portfolio
Cheplapharm owns 7 orange book drugs protected by 14 US patents with Zyprexa having the least patent protection, holding only 1 patent. And Valcyte with maximum patent protection, holding 4 patents. Given below is the list of Cheplapharm's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8889109 | Pharmaceutical dosage forms comprising valganciclovir hydrochloride | 11 Dec, 2027 | Active |
| US9642911 | Pharmaceutical dosage forms comprising valganciclovir hydrochloride | 11 Dec, 2027 | Active |
| US6169084 | 2-methyl-thieno-benzodiazepine formulation | 30 Sep, 2018 | Expired |
| US6004996 | Tetrahydrolipstatin containing compositions | 06 Jul, 2018 | Expired |
| US6142145 | Inhalation device | 08 May, 2018 | Expired |
| US7143764 | Inhalation device | 13 Mar, 2018 | Expired |
| US6027714 | Formulation for inhalation | 09 Jan, 2018 | Expired |
| US6287540 | Formulation for inhalation | 09 Jan, 2018 | Expired |
| US6004996 | Tetrahydrolipstatin containing compositions | 06 Jan, 2018 | Expired |
| US6960577 | Combination therapy for treatment of refractory depression | 01 Nov, 2017 | Expired |
| US6083953 | 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative | 29 Sep, 2015 | Expired |
| US6083953 | 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative | 29 Mar, 2015 | Expired |
| US5472949 | N4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine compounds, compositions and methods of using same | 14 Jun, 2014 | Expired |
| US5472949 | N4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine compounds, compositions and methods of using same | 14 Dec, 2013 | Expired |
Latest Legal Activities on Cheplapharm's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Cheplapharm.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Email Notification
Critical
| 30 Aug, 2022 | US9642911 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 30 Aug, 2022 | US9642911 |
|
Correspondence Address Change
Critical
| 26 Aug, 2022 | US9642911 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 25 Aug, 2022 | US8889109 |
|
Correspondence Address Change
Critical
| 24 Aug, 2022 | US8889109 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Apr, 2022 | US8889109 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Sep, 2020 | US9642911 |
| Surcharge for Late Payment, Large Entity | 21 Aug, 2018 | US8889109 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Aug, 2018 | US8889109 |
|
Maintenance Fee Reminder Mailed
Critical
| 02 Jul, 2018 | US8889109 |
|
Recordation of Patent Grant Mailed
Critical
| 09 May, 2017 | US9642911 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 09 May, 2017 | US9642911 |
|
Email Notification
Critical
| 21 Apr, 2017 | US9642911 |
|
Issue Notification Mailed
Critical
| 19 Apr, 2017 | US9642911 |
| Dispatch to FDC | 06 Apr, 2017 | US9642911 |
Cheplapharm's Drug Patent Litigations
Cheplapharm's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 31, 2005, against patent number US7143764. The petitioner , challenged the validity of this patent, with ALLAN DAGSLAND et al as the respondent. Click below to track the latest information on how companies are challenging Cheplapharm's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7143764 | May, 2005 |
Decision
(31 Mar, 2006)
| ALLAN DAGSLAND et al | |
Cheplapharm's Family Patents
Cheplapharm Drug List
Given below is the complete list of Cheplapharm's drugs and the patents protecting them.
1. Pulmicort Flexhaler
Pulmicort Flexhaler is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6142145 | Inhalation device |
08 May, 2018
(6 years ago)
| Expired |
| US7143764 | Inhalation device |
13 Mar, 2018
(6 years ago)
| Expired |
| US6027714 | Formulation for inhalation |
09 Jan, 2018
(6 years ago)
| Expired |
| US6287540 | Formulation for inhalation |
09 Jan, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pulmicort Flexhaler's drug page
2. Valcyte
Valcyte is protected by 4 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8889109 | Pharmaceutical dosage forms comprising valganciclovir hydrochloride |
11 Dec, 2027
(3 years from now)
| Active |
| US9642911 | Pharmaceutical dosage forms comprising valganciclovir hydrochloride |
11 Dec, 2027
(3 years from now)
| Active |
| US6083953
(Pediatric)
| 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative |
29 Sep, 2015
(9 years ago)
| Expired |
| US6083953 | 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative |
29 Mar, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Valcyte's drug page
3. Xeloda
Xeloda is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5472949
(Pediatric)
| N4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine compounds, compositions and methods of using same |
14 Jun, 2014
(10 years ago)
| Expired |
| US5472949 | N4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine compounds, compositions and methods of using same |
14 Dec, 2013
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xeloda's drug page
4. Xenical
Xenical is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6004996
(Pediatric)
| Tetrahydrolipstatin containing compositions |
06 Jul, 2018
(6 years ago)
| Expired |
| US6004996 | Tetrahydrolipstatin containing compositions |
06 Jan, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xenical's drug page
5. Zyprexa
Zyprexa is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6960577 | Combination therapy for treatment of refractory depression |
01 Nov, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zyprexa's drug page
Explore Our Curated Drug Screens
6. Zyprexa Relprevv
Zyprexa Relprevv is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6169084 | 2-methyl-thieno-benzodiazepine formulation |
30 Sep, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zyprexa Relprevv's drug page
7. Zyprexa Zydis
Zyprexa Zydis is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6960577 | Combination therapy for treatment of refractory depression |
01 Nov, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zyprexa Zydis's drug page